Research Report on Allos Therapeutics, Inc. and Spectrum Pharmaceuticals, Inc. -- BioPharm Looks Forward for Growth
June 17 2011 - 9:00AM
Marketwired
Today, www.EquityMarketsInc.com announced its research report
highlighting Allos Therapeutics, Inc. (NASDAQ: ALTH) and Spectrum
Pharmaceuticals, Inc. (NASDAQ: SPPI). Full content and research is
available at www.EquityMarketsInc.com/research.php.
While it is thought that the recent health care reform
legislation will negatively affect industry profitability over the
next few years, new innovations within the healthcare field have
maintained an influx of new interest to the industry. Combining
medical technology with human touch, the healthcare industry
diagnoses, treats, and administers care around the clock --
responding to the needs of millions of people. Pharmaceuticals
should remain one of the widest-margin industries, with prospects
enhanced by demographic growth in the elderly and new drugs
stemming from discoveries in genomics and biotechnology. Longer
term, it is expected that a wider acceptance of biomarker research
and genetic-targeted clinical studies to help limit expense. It is
viewed that therapeutics for cancer and infectious diseases and
autoimmune and inflammatory treatments are primary growth
areas.
Equity Markets has reviewed Allos Therapeutics, Inc. as a
biopharmaceutical company engaged in the development and
commercialization of anti-cancer therapeutics. The Company is
focused on the development and commercialization of FOLOTYN
(pralatrexate injection). FOLOTYN targets the inhibition of
dihydrofolate reductase (DHFR), an enzyme critical in the folate
pathway, thereby interfering with deoxyribonucleic acid (DNA) and
ribonucleic acid (RNA) synthesis and triggering cancer cell death.
The full research report on Allos Therapeutics, Inc. (NASDAQ: ALTH)
is available here:
www.EquityMarketsInc.com/researchfile4634.php.
Equity Markets is covering Spectrum Pharmaceuticals, Inc. as a
commercial stage biopharmaceutical company, engaged in developing
and commercializing therapies with a focus primarily in the areas
of hematology-oncology and urology. The Company has a fully
developed commercial infrastructure that markets and sells two
drugs in the United States, Zevalin and Fusilev. The Company has
several drug candidates in development, which include apaziquone
(EOquin), which is being studied in two large Phase III clinical
trials for non-muscle invasive bladder cancer (NMIBC). (NASDAQ:
SPPI) is available here:
www.EquityMarketsInc.com/researchfile4891.php.
About Equity Markets Our mission at Equity Markets is to be the
best source of content and research, while educating, enlightening
and informing investors. Equity Markets combines street smart
analysts and professional market researchers to provide investors
with detailed company profiles and market coverage.
Contact: Samuel Littman Email Contact
www.EquityMarketsInc.com
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From May 2024 to Jun 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2023 to Jun 2024